福泰制药(VRTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VRTX 福泰制药

交易中 05-26 11:42:12 EDT

436.54

+2.02

+0.46%

最高441.99	最低433.93	成交量21.54万
今开437.99	昨收434.52	日振幅1.85%
总市值1,108亿	流通市值1,108亿	总股本2.54亿
成交额9,401万	换手率0.08%	流通股本2.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VRTX","market":"US","secType":"STK","nameCN":"福泰制药","latestPrice":436.54,"timestamp":1779810126311,"preClose":434.52,"halted":0,"volume":215389,"delay":0,"changeRate":0.004648807879959585,"floatShares":253718831,"shares":253718831,"eps":16.85,"marketStatus":"交易中","change":2.02,"latestTime":"05-26 11:42:12 EDT","open":437.99,"high":441.99,"low":433.93,"amount":94005689.0329,"amplitude":0.018549,"askPrice":436.55,"askSize":40,"bidPrice":436.17,"bidSize":1,"shortable":3,"etf":0,"ttmEps":16.85,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1779825600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":434.52,"preHourTrading":{"tag":"盘前","latestPrice":437.69,"preClose":434.52,"latestTime":"09:29 EDT","volume":748,"amount":327018.9428,"timestamp":1779802199999,"change":3.17,"changeRate":0.007295,"amplitude":0.045769},"postHourTrading":{"tag":"盘后","latestPrice":433.8,"preClose":434.52,"latestTime":"19:32 EDT","volume":43365,"amount":18841512.3064,"timestamp":1779492750639,"change":-0.72,"changeRate":-0.001657,"amplitude":0.004396},"volumeRatio":0.415677,"impliedVol":0.2156,"impliedVolPercentile":0.0319},"requestUrl":"/m/hq/s/VRTX","defaultTab":"news","newsList":[{"id":"1122799679","title":"福泰制药宣布舒泽曲吉新药上市申请获加拿大卫生部受理，用于治疗成人中重度急性疼痛","url":"https://stock-news.laohu8.com/highlight/detail?id=1122799679","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122799679?lang=zh_cn&edition=full","pubTime":"2026-05-22 01:00","pubTimestamp":1779382813,"startTime":"0","endTime":"0","summary":"福泰制药（Vertex Pharmaceuticals）宣布，其新药舒泽曲吉（Suzetrigine）用于治疗成人中重度急性疼痛的上市申请，已获加拿大卫生部受理并进入审评阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU1035775433.USD","VRTX","LU2417539215.USD","IE00BJJMRZ35.SGD","LU2236285917.USD","LU0058720904.USD","IE00B19Z9P08.USD","LU1674673428.USD","IE0002141913.USD","IE00BJT1NW94.SGD","IE00B19Z9Z06.USD","LU1674673691.USD","IE00B19Z3581.USD","LU2462157665.USD","LU0109394709.USD","LU2362541273.HKD","IE0002270589.USD","IE00B894F039.SGD","SGXZ57979304.SGD","LU0432979614.USD","SG9999013999.USD","LU1430594728.SGD","LU0417517546.SGD","LU1093756325.SGD","LU2456880835.USD","BK4532","IE00B19Z3B42.SGD","LU0061475181.USD","LU1778281490.HKD","LU0234570918.USD","LU2324357040.USD","BK4567","SG9999001176.SGD","BK4588","LU0079474960.USD","IE00BZ9MQY76.HKD","BK4533","SG9999001176.USD","IE00B2B36J28.USD","LU0889565916.HKD","LU1069344957.HKD","LU2237438978.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","IE00BFTCPJ56.SGD","LU2362540622.SGD","LU1093756168.USD","BK4139","IE0009355771.USD","LU1585245621.USD","LU0256863811.USD","BK4585","LU0289739699.SGD","LU2362541513.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149148329","title":"财报前瞻｜福泰制药本季度营收预计小幅增长，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1149148329","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149148329?lang=zh_cn&edition=full","pubTime":"2026-04-27 08:04","pubTimestamp":1777248282,"startTime":"0","endTime":"0","summary":"福泰制药将于2026年05月04日发布新季度财报，市场聚焦核心管线商业化节奏与盈利能力韧性。市场一致预期显示，本季度福泰制药营收预计为30.34亿美元，同比增6.36%；调整后每股收益预计为4.33美元，同比增0.88%；息税前利润预计为12.43亿美元，同比降0.84%。主营业务“产品”收入31.90亿美元，同比增长9.55%，延续稳步增长态势。近期覆盖机构观点以偏多为主。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜福泰制药本季度营收预计小幅增长，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624508187","title":"美国FDA批准福泰制药Alyftrek和Trikafta标签扩展","url":"https://stock-news.laohu8.com/highlight/detail?id=2624508187","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624508187?lang=zh_cn&edition=full","pubTime":"2026-04-02 18:43","pubTimestamp":1775126585,"startTime":"0","endTime":"0","summary":"金吾财讯 | 福泰制药(VRTX)周三表示，美国食品药品监督管理局已批准Alyftrek和Trikafta的标签扩展，用于治疗囊性纤维化患者。更新后的标签现在包括具有任何导致CFTR蛋白生成的CFTR基因变异的患者，这是基于临床和体外数据得出的。此外，富国集团分析师Mohit Bansal维持福泰制药“买入”评级，目标价从515美元上调至550美元。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/ZDhjMmEyODE0Mjk1MzY2MjA4.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZDhjMmEyODE0Mjk1MzY2MjA4.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"298695","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2417539215.USD","IE00B19Z3B42.SGD","LU2362541513.USD","IE00BJT1NW94.SGD","IE00BZ9MQY76.HKD","LABU","LU0061475181.USD","IE0009355771.USD","BK4139","IE00B894F039.SGD","LU0079474960.USD","IE00B19Z9Z06.USD","LU2462157665.USD","IE00BFTCPJ56.SGD","BK4532","LU1035775433.USD","LU0889565916.HKD","LU0417517546.SGD","BK4533","LU1674673691.USD","BK4585","LU0109394709.USD","LU0256863811.USD","IE0002141913.USD","LU2362541273.HKD","LU0058720904.USD","LU1585245621.USD","IE00B19Z3581.USD","LU0320765992.SGD","LU1778281490.HKD","IE00B2B36J28.USD","LU0432979614.USD","LU1093756168.USD","VRTX","IE00BJJMRZ35.SGD","IE00B19Z9P08.USD","LU2456880835.USD","IE0002270589.USD","SG9999001176.USD","BK4588","SG9999001176.SGD","LU0234570918.USD","LU1069344957.HKD","LU2236285917.USD","LU1674673428.USD","SGXZ57979304.SGD","LU2362540622.SGD","BK4567","LU1093756325.SGD","LU1430594728.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144704237","title":"福泰制药宣布美国FDA批准Alyftrek®与Trikafta®标签扩展，覆盖全美约95%囊性纤维化患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1144704237","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144704237?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:30","pubTimestamp":1775043034,"startTime":"0","endTime":"0","summary":"福泰制药近日宣布，其药物Alyftrek®与Trikafta®已获得美国食品药品监督管理局（FDA）的标签扩展批准。这一重要进展将显著扩大两款药物的适用人群范围，预计可使美国约95%的囊性纤维化（CF）患者获得治疗机会。此次标签扩展标志着福泰制药在CF治疗领域取得又一突破，为更广泛的患者群体提供了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU0256863811.USD","LU0109394709.USD","LU1035775433.USD","LU1674673691.USD","LU0889565916.HKD","BK4567","IE00B894F039.SGD","IE00BZ9MQY76.HKD","IE00BFTCPJ56.SGD","LU0289739699.SGD","LU1585245621.USD","SG9999001176.USD","LU1093756168.USD","LU2237438978.USD","IE0002270589.USD","BK4585","IE00B19Z9Z06.USD","LU0823416689.USD","LU2456880835.USD","LU0061475181.USD","IE0009355771.USD","LU2362540622.SGD","LU0417517546.SGD","SG9999001176.SGD","LU0079474960.USD","IE00B2B36J28.USD","BK4533","SGXZ57979304.SGD","LU2362541513.USD","BK4139","LU0320765992.SGD","LU1069344957.HKD","LU1430594728.SGD","LU2417539215.USD","IE00B4R5TH58.HKD","IE00B19Z9P08.USD","LU1778281490.HKD","LU2324357040.USD","BK4588","VRTX","LU0234570918.USD","LU1674673428.USD","LU2462157665.USD","BK4532","IE00BJT1NW94.SGD","LU2362541273.HKD","SG9999013999.USD","IE00BJJMRZ35.SGD","LU0058720904.USD","LU2236285917.USD","IE00B19Z3B42.SGD","IE0002141913.USD","LU0432979614.USD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196872785","title":"福泰制药完成向FDA提交Povetacicept治疗成人IgAN的生物制剂许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1196872785","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196872785?lang=zh_cn&edition=full","pubTime":"2026-04-01 04:21","pubTimestamp":1774988477,"startTime":"0","endTime":"0","summary":"福泰制药（Vertex Pharmaceuticals）宣布，已正式完成向美国食品药品监督管理局（FDA）提交其候选药物Povetacicept针对成人免疫球蛋白A肾病（IgAN）治疗的生物制剂许可申请（BLA）。此次提交标志着该药物在监管审批流程中迈出关键一步。\n根据公开的SEC文件披露，此次BLA提交涵盖了Povetacicept在IgAN患者中的临床数据。若获批，该药物有望为这一缺乏有效治疗手段的疾病领域提供新的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541513.USD","LU1069344957.HKD","IE00B19Z3581.USD","LU0234570918.USD","LU1674673691.USD","LU0889565916.HKD","LU0061475181.USD","LU2324357040.USD","VRTX","IE00B19Z9Z06.USD","LU2362540622.SGD","LU0109394709.USD","BK4139","LU0432979614.USD","IE0002270589.USD","IE00B19Z9P08.USD","IE00B19Z3B42.SGD","IE00B894F039.SGD","IE00BJJMRZ35.SGD","LU1778281490.HKD","LU2417539215.USD","SG9999001176.SGD","SG9999013999.USD","IE00BFTCPJ56.SGD","SGXZ57979304.SGD","LU0256863811.USD","IE00BZ9MQY76.HKD","LU1674673428.USD","LU0289739699.SGD","IE00B4R5TH58.HKD","LU0320765992.SGD","LU2462157665.USD","BK4585","SG9999001176.USD","LU0058720904.USD","BK4567","LU2237438978.USD","LU1430594728.SGD","LU0079474960.USD","LU2456880835.USD","IE00BJT1NW94.SGD","IE0009355771.USD","IE0002141913.USD","LU1093756325.SGD","IE00B2B36J28.USD","BK4533","LU0417517546.SGD","BK4588","LU0823416689.USD","LU1093756168.USD","LU2236285917.USD","BK4532","LU1035775433.USD","LU2362541273.HKD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620933417","title":"新加坡稳定币支付公司 Dtcpay 完成 1000 万美元 A 轮融资，Vertex Ventures 领投","url":"https://stock-news.laohu8.com/highlight/detail?id=2620933417","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620933417?lang=zh_cn&edition=full","pubTime":"2026-03-17 11:57","pubTimestamp":1773719876,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，总部位于新加坡的稳定币支付基础设施公司 Dtcpay 宣布完成 1000 万美元 A 轮融资，由 Vertex Ventures Southeast Asia &amp; India 领投。\n\n该公司已获得卢森堡电子货币机构牌照，以在欧洲经济区扩展受监管的支付服务。Dtcpay 为企业及消费者构建稳定币支付基础设施，并与 Visa 合作推出连接数字金融与传统金融的卡片。其平台支持稳定币与法定货币之间的实时结算。 ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2252400","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","LU1668664300.SGD","IE00BZ9MQY76.HKD","LU1093756168.USD","LU0061475181.USD","LU2360107671.USD","LU0256863811.USD","BK4023","IE0009355771.USD","LU0757428866.USD","IE00BJJMRZ35.SGD","LU0877626530.USD","IE00BJT1NW94.SGD","SG9999013486.USD","LU0188438112.USD","SG9999013999.USD","LU2362541513.USD","IE00B19Z9P08.USD","LU0109394709.USD","LU1119993845.HKD","BK4533","LU0823416689.USD","LU1815336091.USD","IE0002141913.USD","IE00B19Z9Z06.USD","LU0058720904.USD","LU1791807156.HKD","LU0566484027.USD","LU0432979614.USD","LU0106831901.USD","LU2236285917.USD","LU0205439572.USD","LU1861217088.USD","LU1674673428.USD","CCUP","IE00B2B36J28.USD","LU2417539215.USD","CRCO","SGXZ58947870.SGD","BK6523","CRCA","LU0831103253.SGD","LU1839390173.USD","LU2242646235.USD","BK4567","LU2362540622.SGD","BK6033","LU0192582467.USD","LU1585245621.USD","LU0326948709.USD","SG9999000343.SGD","SG9999006266.SGD","LU2242652126.USD","LU2242646821.SGD","SG9999013460.SGD","SG9999001135.SGD","LU2237438978.USD","BK4532","LU0079474960.USD","LU0441851309.USD","LU0898667661.SGD","SG9999003826.SGD","LU1674673691.USD","LU0417517546.SGD","IE00B4R5TH58.HKD","LU1920062954.HKD","LU1861220207.SGD","SG9999001176.SGD","SGXZ57979304.SGD","LU0320765992.SGD","LU1920063259.USD","LU2401740654.USD","BK4585","LU0234570918.USD","LU0889565916.HKD","LU2324357040.USD","LU1069344957.HKD","CRCD","SG9999001176.USD","IE00BFTCPJ56.SGD","LU0289739699.SGD","VRTX","LU1778281490.HKD","SG9999016042.SGD","BK6516","BK4139","SG9999004360.SGD","BK4588","IE00B19Z3581.USD","LU0532188223.SGD","IE00B894F039.SGD","SG9999013478.USD","SG9999001846.SGD","LU1430594728.SGD","ICRC","LU1559883803.SGD","SGXZ27511609.SGD","LU2362541273.HKD","LU2456880835.USD","LU1035775433.USD","IE00B19Z3B42.SGD","IE00BKZH1Z71.USD","SG9999014492.USD","LU2462157665.USD","IE0002270589.USD","SG9999014484.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189008764","title":"盘前异动 | 光通信股续涨，Coherent涨近4%； 福泰制药涨超5%，无人机概念股JOBY涨近5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1189008764","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189008764?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:09","pubTimestamp":1773130152,"startTime":"0","endTime":"0","summary":"3月10日，美股三大股指期货上涨，截止发稿，道指期货涨0.30%，纳指期货涨0.35%，标普500指数期货涨0.29%。加密货币概念股盘前普涨，$Coinbase$、$Circle$、$Strategy$涨超2%，$Robinhood$、$BitMine Immersion$等跟涨。存储概念股上涨，闪迪涨超2%，$美光科技$、$西部数据$、希捷科技涨超1%。美股光通信股盘前续涨，Coherent、Lumentum、$Applied Optoelectronics$均涨近4%；无人机概念股$Joby Aviation$涨近5%，宣布成为美国空中出租车试点项目合作伙伴。慧与科技涨超2%，2026财年Q1营收同比增长18%。","market":"us","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","HPE","LU1861217088.USD","BK4535","COMP.USD.CC","LU2360107671.USD","UNI.USD.HKCC","BK4594","VRTX","TON.USD.HKCC","LTC.USD.HKCC","BK4595","BK4516","LINK.USD.HKCC","COHR","AVAX.USD.HKCC","BK4112","BK4539","BK4601","SNDK","AVAX.USD.CC","BK4588","LU1861220207.SGD","SNX.USD.CC","TON.USD.CC","BK4551","LITE","LU1861558580.USD","BK4554","APT.USD.HKCC","MKR.USD.CC","DOT.USD.CC","APT.USD.CC","LU1861559042.SGD","BK4596","BK4023","COIN","USDT.USD.CC","UNI.USD.CC","BK4600","HIMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618605935","title":"美股异动 | 福泰制药(VRTX.US)盘后大涨 肾脏药物povetacicept后期试验达到预期目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2618605935","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618605935?lang=zh_cn&edition=full","pubTime":"2026-03-10 08:06","pubTimestamp":1773101197,"startTime":"0","endTime":"0","summary":"此前这家生物技术公司表示，其治疗肾脏疾病的药物在后期试验中达到了预期目标，这为其超越囊性纤维化治疗的战略注入了动力。该公司在一份声明中表示，接受povetacicept治疗的患者在 36 周后尿蛋白指标较基线水平降低了52%。福泰制药表示，将于3月底前完成其povetacicept药物向美国食品药品监督管理局的申请，并寻求加速审批程序。福泰制药在2024年以约49亿美元的价格收购Alpine Immune Sciences Inc.时获得了 povetacicept。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | 福泰制药(VRTX.US)盘后大涨 肾脏药物povetacicept后期试验达到预期目标","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B19Z9P08.USD","LU0058720904.USD","LU0256863811.USD","SG9999013999.USD","LU0417517546.SGD","LU2362541273.HKD","LU1778281490.HKD","LU1674673428.USD","LU0289739699.SGD","LU0061475181.USD","LU1585245621.USD","IE00BJJMRZ35.SGD","LU2237438978.USD","IE0002270589.USD","VRTX","LU1430594728.SGD","IE0002141913.USD","SG9999001176.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","LU0234570918.USD","LU2417539215.USD","LU1035775433.USD","LU2456880835.USD","BK4588","LU1093756325.SGD","IE00B19Z3581.USD","SG9999001176.SGD","LU1093756168.USD","IE00B894F039.SGD","IE00B19Z9Z06.USD","BK4567","LU0432979614.USD","BK4532","BK4139","LU1674673691.USD","IE00BZ9MQY76.HKD","SGXZ57979304.SGD","LU0823416689.USD","LU2362540622.SGD","BK4585","LU0079474960.USD","LU2324357040.USD","LU2362541513.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU2462157665.USD","LU0109394709.USD","LU1069344957.HKD","IE00B19Z3B42.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107475635","title":"福泰制药肾病药物试验结果提振股价，盘后大涨6.75%至492美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107475635","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107475635?lang=zh_cn&edition=full","pubTime":"2026-03-10 04:26","pubTimestamp":1773087984,"startTime":"0","endTime":"0","summary":"福泰制药（Vertex Pharmaceuticals）股价在盘后交易时段强势攀升6.75%，报收于492美元。这一显著上涨主要得益于其针对肾病治疗药物的最新临床试验取得了积极成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU2237438978.USD","IE00B2B36J28.USD","LU1093756325.SGD","BK4533","LU0432979614.USD","IE00BJJMRZ35.SGD","LU0256863811.USD","LU1035775433.USD","LU2236285917.USD","SG9999001176.SGD","SG9999013999.USD","IE00BJT1NW94.SGD","IE00BZ9MQY76.HKD","IE00B19Z3581.USD","LU1674673428.USD","LU2362541513.USD","IE00B4R5TH58.HKD","LU0417517546.SGD","LU0289739699.SGD","LU0823416689.USD","LU1585245621.USD","LU2456880835.USD","IE0002141913.USD","BK4567","IE0009355771.USD","BK4585","LU0320765992.SGD","BK4139","LU2362541273.HKD","VRTX","IE00B19Z3B42.SGD","IE00B19Z9P08.USD","BK4588","LU0058720904.USD","IE0002270589.USD","LU0234570918.USD","LU1778281490.HKD","LU2362540622.SGD","LU0109394709.USD","SGXZ57979304.SGD","SG9999001176.USD","LU1093756168.USD","LU0061475181.USD","LU1430594728.SGD","LU2417539215.USD","LU2462157665.USD","LU2324357040.USD","LU1069344957.HKD","IE00B19Z9Z06.USD","LU1674673691.USD","IE00B894F039.SGD","LU0079474960.USD","LU0889565916.HKD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178288150","title":"福泰制药公布IgA肾病患者Povetacicept三期Rainier试验第36周中期分析：主要及全部次要终点结果积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1178288150","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178288150?lang=zh_cn&edition=full","pubTime":"2026-03-10 04:04","pubTimestamp":1773086658,"startTime":"0","endTime":"0","summary":"福泰制药（Vertex Pharmaceuticals）宣布，其在研药物Povetacicept针对成人IgA肾病的三期临床试验（代号Rainier）第36周中期分析结果积极。数据显示，该试验不仅达到主要终点，所有预设的次要终点也均呈现统计学显著改善。这一进展为IgA肾病治疗领域带来新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","SG9999013999.USD","LU2237438978.USD","IE00B19Z3581.USD","LU1035775433.USD","LU0289739699.SGD","IE00BJJMRZ35.SGD","LU0417517546.SGD","BK4533","LU2456880835.USD","BK4567","LU0823416689.USD","LU0320765992.SGD","LU0079474960.USD","IE00B19Z3B42.SGD","LU2236285917.USD","LU2362540622.SGD","VRTX","IE00B19Z9P08.USD","LU1093756325.SGD","LU0109394709.USD","LU1430594728.SGD","LU1674673428.USD","LU1093756168.USD","LU2462157665.USD","IE0009355771.USD","IE00B2B36J28.USD","BK4588","LU0256863811.USD","LU2324357040.USD","IE0002141913.USD","SG9999001176.USD","LU1674673691.USD","IE00BFTCPJ56.SGD","LU0058720904.USD","BK4139","LU2362541273.HKD","IE0002270589.USD","LU2362541513.USD","LU1585245621.USD","LU0234570918.USD","IE00BZ9MQY76.HKD","LU0432979614.USD","BK4532","IE00B894F039.SGD","IE00B19Z9Z06.USD","LU1069344957.HKD","SG9999001176.SGD","BK4585","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU2417539215.USD","SGXZ57979304.SGD","LU0061475181.USD","LU1778281490.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184222646","title":"福泰制药计划三月底前完成Povetacicept的BLA提交 寻求美国加速批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1184222646","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184222646?lang=zh_cn&edition=full","pubTime":"2026-03-10 04:03","pubTimestamp":1773086627,"startTime":"0","endTime":"0","summary":"福泰制药(Vertex Pharmaceuticals)宣布，计划于三月底前完成其在研药物Povetacicept的生物制品许可申请(BLA)提交工作。此举旨在为这款候选药物在美国市场争取加速批准资格。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673691.USD","IE00B4R5TH58.HKD","LU1093756325.SGD","BK4532","IE0009355771.USD","VRTX","LU1069344957.HKD","LU2362540622.SGD","LU1674673428.USD","IE0002141913.USD","LU2362541273.HKD","BK4588","LU1585245621.USD","SG9999001176.SGD","BK4585","LU0234570918.USD","LU1778281490.HKD","BK4567","IE00B19Z9Z06.USD","IE00BJT1NW94.SGD","LU2462157665.USD","SG9999013999.USD","IE00B19Z3581.USD","BK4139","LU0256863811.USD","SG9999001176.USD","LU2456880835.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU0058720904.USD","LU0289739699.SGD","LU0417517546.SGD","IE00B894F039.SGD","IE00BJJMRZ35.SGD","LU0079474960.USD","LU2417539215.USD","SGXZ57979304.SGD","LU0823416689.USD","IE00B19Z3B42.SGD","LU2236285917.USD","BK4533","LU2362541513.USD","IE0002270589.USD","LU2324357040.USD","LU0109394709.USD","IE00B19Z9P08.USD","LU1093756168.USD","LU0061475181.USD","LU1430594728.SGD","LU2237438978.USD","LU0320765992.SGD","LU0432979614.USD","LU0889565916.HKD","IE00BZ9MQY76.HKD","LU1035775433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614022289","title":"Vertex, Inc.盘中异动 早盘股价大涨5.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614022289","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614022289?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:32","pubTimestamp":1772116342,"startTime":"0","endTime":"0","summary":"北京时间2026年02月26日22时32分，Vertex, Inc.股票出现波动，股价快速拉升5.60%。截至发稿，该股报14.14美元/股，成交量8.4226万股，换手率0.05%，振幅1.12%。Vertex, Inc.股票所在的软件服务行业中，整体涨幅为0.95%。Vertex, Inc.公司简介：Vertex Inc是一家提供税务技术和服务的公司。Vertex为特定行业提供基于云和内部部署的解决方案，涵盖收入、销售、消费者使用、增值和工资等各个税种。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226223222a722dcc2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226223222a722dcc2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4023","LU0320765992.SGD","IE00BJJMRZ35.SGD","IE0009355771.USD","LU0757428866.USD","LU2362540622.SGD","SG9999001176.USD","LU2237438978.USD","BK4585","BK4139","IE00BZ9MQY76.HKD","LU2362541273.HKD","LU1559883803.SGD","LU2462157665.USD","SG9999001176.SGD","BK4588","LU0889565916.HKD","LU1069344957.HKD","LU0079474960.USD","LU0058720904.USD","LU2456880835.USD","LU1035775433.USD","IE0002141913.USD","LU1093756168.USD","LU0432979614.USD","LU0061475181.USD","IE00B19Z9Z06.USD","IE00B894F039.SGD","SG9999013999.USD","VERX","LU0256863811.USD","BK4532","LU0234570918.USD","LU0289739699.SGD","LU1430594728.SGD","IE00BJT1NW94.SGD","LU1093756325.SGD","IE00BFTCPJ56.SGD","LU0823416689.USD","LU1778281490.HKD","IE00B2B36J28.USD","VRTX","IE0002270589.USD","LU2236285917.USD","LU0109394709.USD","LU0417517546.SGD","IE00B19Z3B42.SGD","LU0566484027.USD","LU1815336091.USD","SGXZ57979304.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612723489","title":"Vertex, Inc.盘中异动 早盘急速上涨6.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612723489","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612723489?lang=zh_cn&edition=full","pubTime":"2026-02-19 22:31","pubTimestamp":1771511467,"startTime":"0","endTime":"0","summary":"北京时间2026年02月19日22时31分，Vertex, Inc.股票出现异动，股价急速拉升6.53%。Vertex, Inc.股票所在的软件服务行业中，整体跌幅为0.09%。Vertex, Inc.公司简介：Vertex Inc是一家提供税务技术和服务的公司。Vertex为特定行业提供基于云和内部部署的解决方案，涵盖收入、销售、消费者使用、增值和工资等各个税种。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219223107a70a7cc0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219223107a70a7cc0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","IE00B19Z9Z06.USD","LU1430594728.SGD","LU0757428866.USD","SG9999001176.USD","IE00B894F039.SGD","LU0432979614.USD","LU0289739699.SGD","BK4567","IE00B2B36J28.USD","LU1778281490.HKD","LU0079474960.USD","LU1585245621.USD","LU0256863811.USD","LU0109394709.USD","LU0320765992.SGD","LU1069344957.HKD","LU1093756168.USD","LU0417517546.SGD","IE00B4R5TH58.HKD","LU1035775433.USD","BK4139","IE0009355771.USD","LU1674673428.USD","LU0234570918.USD","LU0823416689.USD","LU1093756325.SGD","BK4588","LU1674673691.USD","LU2237438978.USD","LU2362541513.USD","LU2462157665.USD","IE00B19Z9P08.USD","SG9999013999.USD","VRTX","IE00B19Z3B42.SGD","IE00BZ9MQY76.HKD","LU1559883803.SGD","LU2456880835.USD","SG9999001176.SGD","LU0061475181.USD","LU0889565916.HKD","SGXZ57979304.SGD","VERX","IE00BJT1NW94.SGD","IE0002270589.USD","BK4533","LU2236285917.USD","LU2362541273.HKD","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134175666","title":"福泰制药：积极筹备Povetacicept治疗IgAN的近期商业化进程","url":"https://stock-news.laohu8.com/highlight/detail?id=1134175666","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134175666?lang=zh_cn&edition=full","pubTime":"2026-02-13 05:02","pubTimestamp":1770930138,"startTime":"0","endTime":"0","summary":"福泰制药正加速推进Povetacicept针对IgA肾病（IgAN）的近期商业化布局。这款备受关注的治疗药物目前已完成关键临床阶段，公司已启动市场准入策略制定、产能规划及医保谈判等系统性准备工作。随着全球IgAN患者人群的医疗需求持续扩大，该药物的商业化落地有望为福泰制药打开新的增长空间。行业分析师指出，若Povetacicept如期获批，或将重塑自身免疫性疾病治疗领域的市场格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","LU0320765992.SGD","LU1093756168.USD","LU1778281490.HKD","BK4588","BK4533","BK4139","LU0289739699.SGD","LU0889565916.HKD","LU2456880835.USD","SG9999001176.USD","LU2362541513.USD","IE00B19Z9P08.USD","IE00B2B36J28.USD","LU0256863811.USD","SG9999001176.SGD","SG9999013999.USD","IE00BZ9MQY76.HKD","SGXZ57979304.SGD","IE0002270589.USD","BK4567","IE00B19Z3B42.SGD","LU0234570918.USD","BK4585","LU0823416689.USD","LU2237438978.USD","IE00B894F039.SGD","IE0009355771.USD","LU2417539215.USD","LU0109394709.USD","LU0432979614.USD","LU2236285917.USD","LU1585245621.USD","LU0079474960.USD","LU1035775433.USD","LU1069344957.HKD","VRTX","LU1674673691.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU2362540622.SGD","LU2362541273.HKD","BK4532","LU2324357040.USD","LU1093756325.SGD","LU1674673428.USD","IE0002141913.USD","LU2462157665.USD","IE00B19Z9Z06.USD","IE00BJT1NW94.SGD","IE00B19Z3581.USD","LU0417517546.SGD","LU1430594728.SGD","LU0061475181.USD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611213451","title":"Vertex, Inc.盘中异动 临近午盘股价大跌5.18%报12.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611213451","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611213451?lang=zh_cn&edition=full","pubTime":"2026-02-13 00:31","pubTimestamp":1770913890,"startTime":"0","endTime":"0","summary":"北京时间2026年02月13日00时31分，Vertex, Inc.股票出现波动，股价快速跳水5.18%。截至发稿，该股报12.17美元/股，成交量95.6528万股，换手率0.60%，振幅5.57%。Vertex, Inc.股票所在的软件服务行业中，整体跌幅为2.36%。其相关个股中，Chowchow Cloud International Holdings Limited、Fastly, Inc.、Signing Day Sports, Inc.涨幅较大，Signing Day Sports, Inc.、Chowchow Cloud International Holdings Limited、Jet.AI较为活跃，换手率分别为2256.74%、719.94%、262.54%，振幅较大的相关个股有Chowchow Cloud International Holdings Limited、索威尔、Signing Day Sports, Inc.，振幅分别为125.53%、40.56%、38.08%。Vertex, Inc.公司简介：Vertex Inc是一家提供税务技术和服务的公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213003130a49d33da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213003130a49d33da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B19Z3581.USD","LU0256863811.USD","LU0109394709.USD","LU1035775433.USD","LU1559883803.SGD","LU0889565916.HKD","BK4567","LU1674673691.USD","IE00B894F039.SGD","IE00BZ9MQY76.HKD","IE00BFTCPJ56.SGD","LU0289739699.SGD","SG9999001176.USD","LU1093756168.USD","LU2237438978.USD","IE0002270589.USD","LU0823416689.USD","LU2456880835.USD","VERX","LU0061475181.USD","IE0009355771.USD","LU2362540622.SGD","LU0417517546.SGD","SG9999001176.SGD","LU0079474960.USD","IE00B2B36J28.USD","BK4533","SGXZ57979304.SGD","LU2362541513.USD","LU0320765992.SGD","LU1069344957.HKD","LU1430594728.SGD","LU0757428866.USD","LU2324357040.USD","IE00B19Z9P08.USD","LU1778281490.HKD","BK4588","VRTX","LU0234570918.USD","LU1674673428.USD","LU2462157665.USD","IE00BJT1NW94.SGD","LU2362541273.HKD","SG9999013999.USD","IE00BJJMRZ35.SGD","LU2236285917.USD","LU1815336091.USD","LU0566484027.USD","IE0002141913.USD","LU0432979614.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609907547","title":"福泰制药盘中异动 股价大涨3.02%报472.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609907547","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609907547?lang=zh_cn&edition=full","pubTime":"2026-02-07 00:32","pubTimestamp":1770395576,"startTime":"0","endTime":"0","summary":"北京时间2026年02月07日00时32分，福泰制药股票出现异动，股价大幅上涨3.02%。截至发稿，该股报472.66美元/股，成交量42.8508万股，换手率0.17%，振幅2.83%。最近的财报数据显示，该股实现营业收入31.15亿美元，净利润10.83亿美元，每股收益4.24美元，毛利27.01亿美元，市盈率33.22倍。福泰制药股票所在的生物技术行业中，整体涨幅为1.44%。其中福泰疗法仍然是全球治疗囊性纤维化的标准。此外，福泰正在评估APOL1介导的肾脏疾病的小分子抑制剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020700325697a53e48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020700325697a53e48&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2236285917.USD","LU0061475181.USD","BK4532","LU2237438978.USD","IE0002141913.USD","BK4533","LU1778281490.HKD","BK4588","LU2462157665.USD","IE00B19Z3581.USD","LU1674673691.USD","IE00B19Z9Z06.USD","LU0234570918.USD","LU2417539215.USD","LU2362540622.SGD","SG9999001176.USD","LU0823416689.USD","LU1093756325.SGD","LU2362541513.USD","BK4567","BK4139","LU1093756168.USD","LU1585245621.USD","LU2324357040.USD","LU0417517546.SGD","LU2456880835.USD","IE00BJT1NW94.SGD","VRTX","IE00B19Z9P08.USD","SG9999013999.USD","LU0289739699.SGD","SGXZ57979304.SGD","IE0009355771.USD","LU1674673428.USD","LU2362541273.HKD","LU1035775433.USD","BK4585","IE00B19Z3B42.SGD","IE00B2B36J28.USD","LU0256863811.USD","LU1069344957.HKD","LU1430594728.SGD","IE00B4R5TH58.HKD","LU0058720904.USD","LU0109394709.USD","LU0320765992.SGD","LU0432979614.USD","LU0889565916.HKD","IE00B894F039.SGD","SG9999001176.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112986288","title":"财报前瞻｜福泰制药本季度营收预计增14.16%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1112986288","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112986288?lang=zh_cn&edition=full","pubTime":"2026-02-05 10:04","pubTimestamp":1770257088,"startTime":"0","endTime":"0","summary":"福泰制药将于2026年02月12日发布最新季度财报，市场关注核心CF业务韧性与新产品放量带来的增长确定性及盈利质量变化。市场一致预期本季度福泰制药营收为31.74亿美元，同比增长14.16%；毛利率、净利率及调整后每股收益的具体本季度预测，市场未给出足够一致的量化数据；本季度预测的每股收益为5.07美元，同比增长25.87%，息税前利润为14.46亿美元，同比增长23.59%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜福泰制药本季度营收预计增14.16%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608350097","title":"药明生物与Vertex达成TCE合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2608350097","media":"医药健闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608350097?lang=zh_cn&edition=full","pubTime":"2026-02-04 15:09","pubTimestamp":1770188940,"startTime":"0","endTime":"0","summary":" CRDMO药明生物宣布，已与Vertex Pharmaceuticals Incorporated签署一项针对创新三特异性T细胞衔接子的授权和研究服务协议，该TCE用于治疗B细胞介导的自身免疫性疾病。根据协议，Vertex拥有该处于临床前阶段的创新三特异性TCE的全球独家开发和商业化权利。药明生物将获得首付款，并有资格获得开发、监管和销售里程碑付款以及特许权使用费，同时还将为Vertex提供新一代TCE的合同研发服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204151000a6d1a8e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204151000a6d1a8e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1430594728.SGD","LU0256863811.USD","VERX","LU2417539215.USD","LU1585245621.USD","BK4532","LU0061475181.USD","SG9999001176.SGD","LU0058720904.USD","SGXZ57979304.SGD","LU2362541273.HKD","BK4567","LU1674673691.USD","LU0289739699.SGD","LU0823416689.USD","VRTX","IE00BFTCPJ56.SGD","LU0757428866.USD","LU0417517546.SGD","BK4585","LU0566484027.USD","LU1069344957.HKD","LU1093756325.SGD","LU1778281490.HKD","LU0234570918.USD","SG9999001176.USD","LU0889565916.HKD","IE0002141913.USD","LU0320765992.SGD","LU0109394709.USD","IE00B19Z9P08.USD","LU0432979614.USD","LU2324357040.USD","BK4588","LU2462157665.USD","LU2362541513.USD","IE0002270589.USD","IE00BZ9MQY76.HKD","IE00B19Z3B42.SGD","BK4139","LU1093756168.USD","IE00B19Z9Z06.USD","BK4023","LU2362540622.SGD","IE00B894F039.SGD","LU0079474960.USD","LU2236285917.USD","BK4533","IE00B4R5TH58.HKD","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608438490","title":"英硅智能获里程碑付款；药明生物与Vertex达成合作|21健讯Daily","url":"https://stock-news.laohu8.com/highlight/detail?id=2608438490","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608438490?lang=zh_cn&edition=full","pubTime":"2026-02-04 08:09","pubTimestamp":1770163752,"startTime":"0","endTime":"0","summary":"这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！政策动向上海：大力培育发展脑机接口等未来产业上海市第十六届人大四次会议2月3日上午在世博中心开幕。上海市市长龚正作《政府工作报告》。报告表示，今年要推进临港科创城建设，加快打造一批高水平科创社区，持续提升东方芯港、大飞机园等特色产业园区能级，大力培育发展脑机接口、第四代半导体等未来产业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602043640744690.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602043640744690.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BZ9MQY76.HKD","LU0456827905.SGD","BK4532","LU2237438978.USD","IE0002141913.USD","BK4533","02269","LU0856984785.SGD","IE00B19Z3581.USD","LU0039217434.USD","LU0417516738.SGD","BK1589","SG9999002562.SGD","LU2417539215.USD","LU0516423174.USD","LU0516422366.SGD","BK1521","LU3063872942.SGD","BK4567","BK1610","IE00BFTCPJ56.SGD","LU0348735423.USD","LU1093756168.USD","LU1585245621.USD","LU0516423091.SGD","VERX","LU0326950275.SGD","LU1242518931.SGD","IE00B0JY6N72.USD","LU0417517546.SGD","LU2456880835.USD","IE00BJT1NW94.SGD","LU0359202008.SGD","LU0043850808.USD","VRTX","LU1688375341.USD","SG9999013999.USD","IE0009355771.USD","LU1674673428.USD","LU2362541273.HKD","IE00B2B36J28.USD","BK4023","IE0002270589.USD","LU1430594728.SGD","LU0708995583.HKD","LU0109394709.USD","LU0052750758.USD","LU0320765992.SGD","IE00B894F039.SGD","LU0456846285.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608581451","title":"药明生物与Vertex就创新三特异性T细胞衔接子达成授权和研究服务协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2608581451","media":"人民财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608581451?lang=zh_cn&edition=full","pubTime":"2026-02-03 08:47","pubTimestamp":1770079632,"startTime":"0","endTime":"0","summary":"人民财讯2月3日电，2月3日，药明生物宣布与VertexPharmaceuticals（纳斯达克代码：VRTX）已针对一款创新三特异性T细胞衔接子（TCE）签署授权和研究服务协议。Vertex计划用于治疗B细胞介导的自身免疫性疾病。根据协议条款，Vertex将获得该处于临床前阶段、计划用于治疗B细胞介导的自免疾病的三特异性TCE的全球独家开发及商业化权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602033639376886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0823426308.USD","LU2462157665.USD","LU0327786744.USD","BK4585","02269","LU1035775433.USD","IE00B2B36J28.USD","LU0823426480.USD","LU0061475181.USD","LU2362541513.USD","BK1589","LU1674673428.USD","VRTX","IE00B19Z3B42.SGD","BK1521","LU0234570918.USD","LU0320765992.SGD","SG9999002562.SGD","LU1815336091.USD","LU0417516902.SGD","LU0058720904.USD","LU0856984785.SGD","LU2362541273.HKD","BK4588","LU0307460666.USD","LU0181495838.USD","BK1610","LU0348735423.USD","LU0348825331.USD","LU0456827905.SGD","LU0819121731.USD","LU0456846285.SGD","LU1880383366.USD","SG9999013999.USD","LU1242518857.USD","LU0566484027.USD","IE00B894F039.SGD","LU2324357040.USD","IE00B0JY6N72.USD","LU0516422440.USD","LU0979878070.USD","LU1674673691.USD","LU0359202008.SGD","LU1720050803.USD","IE00BJJMRZ35.SGD","LU1093756325.SGD","LU0289739699.SGD","VERX","LU0516423091.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vrtx.com","stockEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":-0.0072},{"period":"3month","weight":-0.0889},{"period":"6month","weight":0.0182},{"period":"1year","weight":0.0011},{"period":"ytd","weight":-0.0416}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Vertex Pharmaceuticals Incorporated于1989年在马萨诸塞州注册成立，是一家全球性的生物技术公司，致力于科学创新，旨在为患有严重疾病的个人，特别是在专业市场创造变革性药物。该公司已开发出针对囊性纤维化、镰状细胞病、输血依赖性β地中海贫血和急性疼痛等病症的获批疗法。该公司不断创新，推进跨越各种严重疾病的下一代临床和研究项目，包括IgA肾病和1型糖尿病等。","yearOnYearQuotes":[{"month":1,"riseRate":0.657143,"avgChangeRate":0.034393},{"month":2,"riseRate":0.457143,"avgChangeRate":0.001601},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.021959},{"month":4,"riseRate":0.6,"avgChangeRate":0.01636},{"month":5,"riseRate":0.571429,"avgChangeRate":0.076072},{"month":6,"riseRate":0.558824,"avgChangeRate":0.028419},{"month":7,"riseRate":0.470588,"avgChangeRate":-0.004622},{"month":8,"riseRate":0.628571,"avgChangeRate":0.046325},{"month":9,"riseRate":0.485714,"avgChangeRate":0.030192},{"month":10,"riseRate":0.542857,"avgChangeRate":0.000856},{"month":11,"riseRate":0.485714,"avgChangeRate":-0.02026},{"month":12,"riseRate":0.657143,"avgChangeRate":0.071588}],"exchange":"NASDAQ","name":"福泰制药","nameEN":"Vertex Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"福泰制药(VRTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供福泰制药(VRTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"福泰制药,VRTX,福泰制药股票,福泰制药股票老虎,福泰制药股票老虎国际,福泰制药行情,福泰制药股票行情,福泰制药股价,福泰制药股市,福泰制药股票价格,福泰制药股票交易,福泰制药股票购买,福泰制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"福泰制药(VRTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供福泰制药(VRTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}